California AB 2030 Restricts Weight Loss, Muscle Building Supplements for Minors

Sacramento, California — 05 October 2026

California has enacted Assembly Bill (AB) 2030, establishing new age restrictions for certain dietary supplements marketed for weight loss and muscle building. Effective 1 January 2027, the legislation prohibits the sale of these specified products to individuals under 18 years of age. This move targets supplements containing ingredients such as creatine, DHEA, ephedra, and specific stimulants when promoted for weight management or muscle development. Retailers, including pharmacies and online platforms, are now mandated to implement robust age verification systems at the point of sale, with non-compliance incurring civil penalties. The legislation explicitly tasks the California Department of Public Health (CDPH) with publishing a comprehensive list of restricted ingredients and product types by July 2026, providing manufacturers with a critical compliance roadmap.

This regulatory development follows increasing concern regarding the potential health risks associated with the unsupervised use of these supplements by minors. Industry analysts predict this could trigger a nationwide trend, as other states often adopt California's regulatory frameworks. The fragmentation of state-level regulations will necessitate a more granular approach to market compliance for manufacturers and brand owners operating across the US. This regulatory shift will require re-evaluating product positioning, labelling, and distribution channels to ensure strict adherence, particularly for brands with a significant presence in the Californian market.

While the immediate impact targets specific supplement categories, the broader implication is increased scrutiny of ingredient safety and claims substantiation for products consumed by younger demographics. Brands may need to invest further in clinical substantiation or opt for reformulation to remove or replace targeted ingredients to retain market access or expand their consumer base beyond the minor age group. This legislative action highlights the need for continuous monitoring of state-level regulatory developments, as local initiatives increasingly dictate market parameters for the dietary supplement industry.

What this means for United States

US manufacturers and brand owners must conduct an immediate portfolio review to identify products susceptible to AB 2030. Compliance with the January 2027 deadline necessitates implementing new age-gating processes for both online and brick-and-mortar sales in California, incurring estimated setup costs of $5,000 to $20,000 per sales channel. Reformulation windows, typically 6-12 months, are now critical for brands wishing to retain the minor demographic with compliant alternatives. Failure to comply poses competitive threats, risking civil penalties of up to $2,500 per violation and market share loss to compliant competitors.

Separately, a new precision fermentation facility in France, with a planned Q3 2027 operational date, targets accelerating biotech ingredient innovation across Europe. This initiative aims to address existing supply chain vulnerabilities and reduce lead times for novel bioactive compounds. Concurrently, PDRN (Polydeoxyribonucleotide) is gaining traction as a next-generation beauty supplement ingredient in South Korea, driven by K-beauty trends. This ingredient, derived from salmon DNA, targets skin rejuvenation and repair, presenting a new premium segment opportunity for brands seeking differentiated offerings.

Brand owners increasingly rely on contract-manufacturing partners such as Supplement Factory to navigate these requirements.